アブストラクト
| Title | 今後のIBD治療薬の展望 |
|---|---|
| Subtitle | 特集 Evidence & Consensusで押さえる IBDの治療薬 最新版 今後の適切なIBD治療に向けて |
| Authors | 竹中健人, 渡辺守 |
| Authors (kana) | |
| Organization | 東京医科歯科大学消化器内科 |
| Journal | 月刊薬事 |
| Volume | 64 |
| Number | 12 |
| Page | 2522-2526 |
| Year/Month | 2022 / 9 |
| Article | 報告 |
| Publisher | じほう |
| Abstract | [Key Point] ●炎症性腸疾患は, 潰瘍性大腸炎およびクローン病に代表される原因不明の慢性腸疾患で根本治療はない. ●既存の薬剤を用いても治療に難渋する症例も存在し, 長い寛解維持効果や安全性の確保も重要な課題である. ●新たな治療薬として, 「炎症サイトカインを標的とする薬剤」および「炎症細胞の遊走を標的とする薬剤」に大きく分類される. ●一人ひとりの病態に応じて各薬剤を適切に使い分け, 患者ごとの個別化治療をいかに進めていくかが課題である. |
| Practice | 薬学 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に803円(税込) です。
参考文献
- 1) D'Haens GR, et al : Risankizumab induction therapy in patients with moderate-to-severe Crohn's disease with intolerance or inadequate response to conventional and/or biologic therapy : Results from the phase 3 ADVANCE Study. Gastroenterology, 161 : e28, 2021
- 2) Sandborn WJ, et al : Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with ulcerative colitis. Gastroenterology, 158 : 537-549.e10, 2020
- 3) Sandborn W, et al : The Efficacy and Safety of Guselkumab Induction Therapy in Patients with Moderately to Severely Active Crohn's Disease : Week 12 Interim Analyses from the Phase 2 GALAXI 1 Study. (Abstract OP089)UEG Week Virtual 2020, 2020
- 4) Vermeire S, et al : Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib(the FITZROY study) : results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet, 389 : 266-275, 2017
- 5) Sandborn WJ, et al : Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn's disease. Gastroenterology, 158 : 2123-2138.e8, 2020
残りの7件を表示する
- 6) Danese S, et al : Effects of apremilast, an oral inhibitor of phosphodiesterase 4, in a randomized trial of patients with active ulcerative colitis. Clin Gastroenterol Hepatol, 18 : 2526-2534.e9, 2020
- 7) Danese S, et al : Safety, tolerability and efficacy of anti-TLlA antibody PF-06480605 in treatment of ulcerative colitis : The open-label, multicentre, phase 2a TUSCANY study. J Crohns Colitis, 14 : S108-S110, 2020
- 8) Matsuoka K, et al : AJM300(carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis : a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Gastroenterol Hepatol, 7 : 648-657, 2022
- 9) Sandborn WJ, et al : Efficacy and safety of abrilumab in a randomized, placebo-controlled trial for moderate-to-severe ulcerative colitis. Gastroenterology, 156 : 946-957.e18, 2019
- 10) Danese S, et al : Ozanimod as maintenance therapy in patients with moderate-to-severe ulcerative colitis : Results from the phase 3, randomized. double-blind. placebo-controlled True North study. Paper presented in late-breaking oral presentation. (#LBlO)UEG Week Virtual 2020, 2020
- 11) Sugahara K, et al : Amiselimod, a novel sphingosine 1-phosphate receptor-1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk. Br J Pharmacol, 174 : 15-27, 2017
- 12) Sandborn WJ, et al : Efficacy and safety of etrasimod in a phase 2 randomized trial of patients with ulcerative colitis. Gastroenterology, 158 : 550-561, 2020
